IL145714A0 - Prediction of risk of interstitial lung disease - Google Patents

Prediction of risk of interstitial lung disease

Info

Publication number
IL145714A0
IL145714A0 IL14571400A IL14571400A IL145714A0 IL 145714 A0 IL145714 A0 IL 145714A0 IL 14571400 A IL14571400 A IL 14571400A IL 14571400 A IL14571400 A IL 14571400A IL 145714 A0 IL145714 A0 IL 145714A0
Authority
IL
Israel
Prior art keywords
prediction
risk
lung disease
interstitial lung
interstitial
Prior art date
Application number
IL14571400A
Other languages
English (en)
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of IL145714A0 publication Critical patent/IL145714A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14571400A 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease IL145714A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28610899A 1999-04-02 1999-04-02
PCT/US2000/008492 WO2000060117A2 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease

Publications (1)

Publication Number Publication Date
IL145714A0 true IL145714A0 (en) 2002-07-25

Family

ID=23097113

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14571400A IL145714A0 (en) 1999-04-02 2000-03-31 Prediction of risk of interstitial lung disease

Country Status (6)

Country Link
EP (1) EP1192275A2 (de)
JP (1) JP2002540801A (de)
AU (1) AU779701B2 (de)
CA (1) CA2367294A1 (de)
IL (1) IL145714A0 (de)
WO (1) WO2000060117A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002031197A1 (en) * 2000-10-10 2002-04-18 Wunderink Richard G Method for identifying increased risk of death from community acquired pneumonia
AU2002347182A1 (en) * 2001-12-18 2003-06-30 Mondobiotech Licensing Out Ag Pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US20030148288A1 (en) * 2002-02-01 2003-08-07 Yi-Wei Tang Colorimetric genetic test for clinically significant TNF polymorphism and methods of use thereof
CN1711361A (zh) * 2002-10-15 2005-12-21 诺瓦提斯公司 预测药物治疗副效应水肿的方法
WO2006100446A2 (en) * 2005-03-23 2006-09-28 Astrazeneca Uk Limited Method of diagnosing interstitial lung disease (ild)
US7933722B2 (en) 2005-05-20 2011-04-26 Synergenz Bioscience Limited Methods of analysis of polymorphisms and uses thereof
US8748101B2 (en) * 2008-11-10 2014-06-10 Battelle Memorial Institute Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions
WO2013092810A1 (en) * 2011-12-21 2013-06-27 University College Dublin, National University Of Ireland, Dublin Methods relating to idiopathic pulmonary fibrosis (ipf)
EP2963126B1 (de) * 2013-03-01 2019-04-03 Saitama Medical University Verfahren zur bewertung des risikos des einsetzens von nebenwirkungen in einer medikamentösen krebsbehandlung, einschliesslich des nachweises von muc4-genpolymorphismus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118119C (en) * 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
US5942390A (en) * 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
AU760856B2 (en) * 1997-05-29 2003-05-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for chronic obstructive airway disease

Also Published As

Publication number Publication date
AU4183700A (en) 2000-10-23
AU779701B2 (en) 2005-02-10
WO2000060117A2 (en) 2000-10-12
EP1192275A2 (de) 2002-04-03
CA2367294A1 (en) 2000-10-12
WO2000060117A3 (en) 2002-02-07
JP2002540801A (ja) 2002-12-03

Similar Documents

Publication Publication Date Title
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL160884A0 (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
GB9723553D0 (en) Prediction of the risk of chronic obstructive airway disease
GB0013515D0 (en) Endoscope
IL144981A0 (en) Treatment of autoimmune disease
IL160998A0 (en) Human tissue factor antibodies
EP1429775A4 (de) Verfahren zur behandlung von lungenerkrankungen
GB0004531D0 (en) The treatment of respiratory diseases
GB0023915D0 (en) Treatment of neuroinflammatory disease
IL145714A0 (en) Prediction of risk of interstitial lung disease
IL147946A0 (en) Treatment of inflammatory or malignant disease using dnazymes
GB2353477B (en) Medical endoscope
GB9927757D0 (en) Treatment of autoimmune diseases
GB0001443D0 (en) Medical endoscope
EP1107778A4 (de) Behandlung von krankheitszuständen
GB0029524D0 (en) Disease treatment
GB9825948D0 (en) Diagnosis of spongiform disease
GB0003921D0 (en) Medical endoscopes
EP1426762A4 (de) Mittel gegen herzkrankheiten
SI1242060T1 (sl) Zdravljenje metastatske bolezni
GB9919565D0 (en) Treatment of disease
EP1221951A4 (de) Behandlung von pankreas-erkrankungen
AU2002365654A8 (en) Treatment of diseases via the skin
GB0112330D0 (en) Treatment of degenerative lung disease
TW411783U (en) Improved structure of shoes